Maria T Grosse Perdekamp | Carle ...

Dr. Maria T. Grosse-Perdekamp

Claim this profile

Carle Cancer Center

Expert in Breast Cancer
Studies Breast cancer
31 reported clinical trials
62 drugs studied

About Maria T. Grosse-Perdekamp

Education:

  • Earned an MD (Doctor of Medicine), with the institution not specified.
  • Completed a Residency in Radiation Oncology at Carle Foundation Hospital in 2019.
  • Undertook a Fellowship in Brachytherapy at Carle Foundation Hospital in 2020.

Experience:

  • Currently serves as a Radiation Oncologist at Carle Cancer Center.

Area of expertise

1

Breast Cancer

Global Leader

Maria T. Grosse-Perdekamp has run 14 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
HER2 negative
Stage II
2

Breast Cancer

Maria T. Grosse-Perdekamp has run 10 trials for Breast cancer. Some of their research focus areas include:

HER2 positive
ER negative
HER2 negative

Affiliated Hospitals

Image of trial facility.

Carle Cancer Center

Image of trial facility.

Carle Physician Group-Effingham

Clinical Trials Maria T. Grosse-Perdekamp is currently running

Image of trial facility.

Triptorelin

for Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Mobile Health

for Breast Cancer

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.

Recruiting

1 award

N/A

10 criteria

More about Maria T. Grosse-Perdekamp

Clinical Trial Related

3 years of experience running clinical trials · Led 31 trials as a Principal Investigator · 11 Active Clinical Trials

Treatments Maria T. Grosse-Perdekamp has experience with

  • Paclitaxel
  • Biospecimen Collection
  • Atezolizumab
  • Carboplatin
  • Palbociclib
  • Docetaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Maria T. Grosse-Perdekamp specialize in?

Is Maria T. Grosse-Perdekamp currently recruiting for clinical trials?

Are there any treatments that Maria T. Grosse-Perdekamp has studied deeply?

What is the best way to schedule an appointment with Maria T. Grosse-Perdekamp?

What is the office address of Maria T. Grosse-Perdekamp?

Is there any support for travel costs?